Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Sep;30(3):476–480. doi: 10.1111/j.1365-2125.1990.tb03800.x

Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.

M L Dahl-Puustinen 1, C Alm 1, L Bertilsson 1, I Christenson 1, J Ostman 1, E Thunberg 1, I Wikström 1
PMCID: PMC1368152  PMID: 2121211

Abstract

The pharmacokinetics of a single oral dose of 1.75 mg glibenclamide were studied in 15 healthy Caucasians including five poor metabolisers of debrisoquine and five poor metabolisers of S-mephenytoin. Plasma glibenclamide concentrations and the urinary concentrations of trans-4- and cis-3-hydroxyglibenclamide were analyzed by h.p.l.c. Thirty-six +/- 6% (mean +/- s.d., n = 15) of the given dose of glibenclamide was excreted in 48 h urine as hydroxylated metabolites, 27 +/- 4% as trans-4-hydroxyglibenclamide and 8 +/- 2% as cis-3-hydroxyglibenclamide. There were no differences in the plasma pharmacokinetics of glibenclamide or in the urinary excretion of the metabolites between poor and extensive metabolisers of debrisoquine, neither between the two mephenytoin hydroxylator phenotypes. The study thus indicates that the disposition of glibenclamide is not influenced by these two independent polymorphisms of drug oxidation.

Full text

PDF
476

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asplund K., Wiholm B. E., Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia. 1983 Jun;24(6):412–417. doi: 10.1007/BF00257338. [DOI] [PubMed] [Google Scholar]
  2. Balant L., Fabre J., Zahnd G. R. Comparison of the pharmacokinetics of glipizide and glibenclamide in man. Eur J Clin Pharmacol. 1975;8(1):63–69. doi: 10.1007/BF00616416. [DOI] [PubMed] [Google Scholar]
  3. Bertilsson L., Henthorn T. K., Sanz E., Tybring G., Säwe J., Villén T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther. 1989 Apr;45(4):348–355. doi: 10.1038/clpt.1989.40. [DOI] [PubMed] [Google Scholar]
  4. Brøsen K., Gram L. F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol. 1989;36(6):537–547. doi: 10.1007/BF00637732. [DOI] [PubMed] [Google Scholar]
  5. Emilsson H., Sjöberg S., Svedner M., Christenson I. High-performance liquid chromatographic determination of glibenclamide in human plasma and urine. J Chromatogr. 1986 Nov 28;383(1):93–102. doi: 10.1016/s0378-4347(00)83445-3. [DOI] [PubMed] [Google Scholar]
  6. Knodell R. G., Dubey R. K., Wilkinson G. R., Guengerich F. P. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther. 1988 Jun;245(3):845–849. [PubMed] [Google Scholar]
  7. Küpfer A., Branch R. A. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther. 1985 Oct;38(4):414–418. doi: 10.1038/clpt.1985.196. [DOI] [PubMed] [Google Scholar]
  8. Küpfer A., Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol. 1984;26(6):753–759. doi: 10.1007/BF00541938. [DOI] [PubMed] [Google Scholar]
  9. Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E., Wilkinson G. R., Branch R. A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985 Oct;38(4):402–408. doi: 10.1038/clpt.1985.194. [DOI] [PubMed] [Google Scholar]
  10. Peart G. F., Boutagy J., Shenfield G. M. The metabolism of glyburide in subjects of known debrisoquin phenotype. Clin Pharmacol Ther. 1989 Mar;45(3):277–284. doi: 10.1038/clpt.1989.28. [DOI] [PubMed] [Google Scholar]
  11. Rupp W., Christ O., Heptner W. Resorption, Ausscheidung und Metabolismus nach intravenöser und oraler Gabe von HB 419-14C an Menschen. Arzneimittelforschung. 1969 Aug;19(8 Suppl):1428–1434. [PubMed] [Google Scholar]
  12. Sartor G., Melander A., Scherstén B., Wåhlin-Boll E. Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide. Diabetologia. 1980 Jan;18(1):17–22. doi: 10.1007/BF01228296. [DOI] [PubMed] [Google Scholar]
  13. Steiner E., Bertilsson L., Säwe J., Bertling I., Sjöqvist F. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther. 1988 Oct;44(4):431–435. doi: 10.1038/clpt.1988.176. [DOI] [PubMed] [Google Scholar]
  14. Ward S. A., Walle T., Walle U. K., Wilkinson G. R., Branch R. A. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther. 1989 Jan;45(1):72–79. doi: 10.1038/clpt.1989.11. [DOI] [PubMed] [Google Scholar]
  15. Wåhlin-Boll E., Melander A. High-performance liquid chromatographic determination of glipizide and some other sulfonylurea drugs in serum. J Chromatogr. 1979 Dec 1;164(4):541–546. doi: 10.1016/s0378-4347(00)81560-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES